Commerce Bank increased its stake in Zoetis Inc. (NYSE:ZTS) by 4.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 89,305 shares of the company’s stock after purchasing an additional 4,103 shares during the quarter. Commerce Bank’s holdings in Zoetis were worth $5,694,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after purchasing an additional 230 shares during the period. Harfst & Associates Inc. raised its holdings in Zoetis by 16.1% during the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after acquiring an additional 260 shares during the period. Almanack Investment Partners LLC. bought a new stake in Zoetis during the 2nd quarter valued at $119,000. Peddock Capital Advisors LLC bought a new stake in Zoetis during the 2nd quarter valued at $140,000. Finally, Shine Investment Advisory Services Inc. raised its holdings in Zoetis by 86.5% during the 3rd quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock valued at $143,000 after acquiring an additional 1,040 shares during the period. 92.44% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Commerce Bank Boosts Position in Zoetis Inc. (ZTS)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/11/17/commerce-bank-boosts-position-in-zoetis-inc-zts.html.

Shares of Zoetis Inc. (NYSE ZTS) traded up $0.79 during trading hours on Friday, hitting $70.41. 2,055,500 shares of the stock traded hands, compared to its average volume of 2,808,289. The company has a market capitalization of $34,440.00, a P/E ratio of 31.94, a price-to-earnings-growth ratio of 2.03 and a beta of 1.02. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. Zoetis Inc. has a 52-week low of $48.55 and a 52-week high of $70.49.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.63 by $0.02. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.52 earnings per share. equities research analysts expect that Zoetis Inc. will post 2.37 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Thursday, November 9th will be paid a dividend of $0.105 per share. This represents a $0.42 annualized dividend and a dividend yield of 0.60%. The ex-dividend date of this dividend is Wednesday, November 8th. Zoetis’s dividend payout ratio (DPR) is 22.11%.

ZTS has been the topic of a number of analyst reports. BMO Capital Markets reissued a “hold” rating and set a $65.00 target price on shares of Zoetis in a report on Thursday, November 2nd. Cantor Fitzgerald set a $75.00 target price on shares of Zoetis and gave the company a “buy” rating in a report on Monday, August 14th. Cowen and Company set a $80.00 price target on shares of Zoetis and gave the stock a “buy” rating in a report on Friday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $65.00 price target on shares of Zoetis in a report on Friday, September 1st. Finally, BidaskClub cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 20th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the stock. Zoetis has a consensus rating of “Buy” and a consensus price target of $67.65.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.